Clinical Trials Logo

Post-Menopausal Osteoporosis clinical trials

View clinical trials related to Post-Menopausal Osteoporosis.

Filter by:

NCT ID: NCT01224717 Completed - Clinical trials for Post-menopausal Osteoporosis

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women

Start date: September 2010
Phase: Phase 1
Study type: Interventional

This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.

NCT ID: NCT00984893 Completed - Clinical trials for Post-Menopausal Osteoporosis

Intra-venous Zoledronic Acid Once Yearly

IVORY
Start date: November 2008
Phase: N/A
Study type: Observational

The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment. Zoledronic acid will be compared to oral bisphosphonates (OBP) with respect to the change in Bone Mineral Density (BMD) and incidence of fractures.

NCT ID: NCT00718861 Completed - Clinical trials for Post-menopausal Osteoporosis

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

Start date: May 2008
Phase: Phase 3
Study type: Interventional

This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis

NCT ID: NCT00666627 Completed - Clinical trials for Post-menopausal Osteoporosis

Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects

Start date: April 2007
Phase: Phase 2
Study type: Interventional

A study to determine if the three licensed bisphosphonates (alendronate, ibandronate and risedronate):a) affect the peripheral skeleton differently, as assessed by quantitative ultrasound of bone (QUS), peripheral quantitative computed tomography (pQCT) and dual−energy x−ray absorptiometry (DXA)? b) have different effects on bone cells and their activity as assessed by flow cytometry and biochemical markers of bone cell activity? The aim of the study is to compare the effects of three licensed bisphosphonates on bone quantity and quality. There has been no such study before. Most of the measures of bone quantity and quality used in this protocol have not been studied with any of these three agents. The novelty of the study necessitates the establishment of reference ranges and this explains the need for the inclusion of a group of young women.

NCT ID: NCT00551174 Completed - Clinical trials for Post-Menopausal Osteoporosis

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment

Start date: October 2004
Phase: Phase 4
Study type: Interventional

This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550 (DIVA study; NCT00048074). Patients received Bonviva either 2 mg IV every 2 months, or 3 mg IV every 3 months. Patients also received daily supplementation with vitamin D and calcium. The anticipated time on study treatment was 2+ years, and the target sample size was 500+ individuals.

NCT ID: NCT00545779 Completed - Clinical trials for Post-Menopausal Osteoporosis

BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.

Start date: December 2006
Phase: Phase 4
Study type: Interventional

This single arm study will assess patient preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. Patients currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate) will answer a questionnaire to identify patients who may benefit from a monthly Bonviva regimen. Eligible patients will then discontinue their present bisphosphonate treatment, and switch to monthly Bonviva 150mg po. At the beginning and end of Bonviva treatment, all patients will complete an Osteoporosis Patient Satisfaction Questionnaire. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00545480 Completed - Clinical trials for Post Menopausal Osteoporosis

SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.

Start date: July 2006
Phase: Phase 4
Study type: Interventional

This 2 arm study will assess the impact of bone marker feedback, using blood sampling and communication of results at week 5, on persistence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis. The study will also assess safety, quality of life and patient satisfaction. All patients will receive Bonviva 150mg po monthly, and will be randomized into the bio-feedback or no bio-feedback study arms. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00545090 Completed - Clinical trials for Post Menopausal Osteoporosis

ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Start date: August 2006
Phase: Phase 4
Study type: Interventional

This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study. All patients completing 6 months in ML19930 will continue to receive Bonviva (150mg po, monthly) for an additional 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00533650 Completed - Clinical trials for Post-Menopausal Osteoporosis

Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)

Start date: December 2000
Phase: Phase 2
Study type: Interventional

A study to asses the safety and efficacy of MK0429 in postmenopausal women with osteoporosis.

NCT ID: NCT00503113 Completed - Clinical trials for Post-Menopausal Osteoporosis

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

Start date: July 2007
Phase: Phase 4
Study type: Interventional

This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal disease. Patients will be randomized to receive Bonviva 3mg intravenous (iv) by a) injection or b) infusion once every 3 months, or alendronate 70mg per oral (po) weekly. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.